Effect of carbamazepine on the pharmacokinetics of promazine

Polish Journal of Pharmacology

Volumn 48, Issue 6, 1996, Pages 601-608

  Syrek, Maciej ^a   Wójcikowski, Jacek ^a   Daniel, Władysława ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

brain; carbamazepine; concentration; cytochro me P 450; interaction; metabolism; plasma; promazine

Indexed keywords

CARBAMAZEPINE; DRUG METABOLITE; NEUROLEPTIC AGENT; PROMAZINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; COMPETITIVE INHIBITION; CONTROLLED STUDY; DEMETHYLATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG METABOLISM; ENZYME INDUCTION; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; OXIDATION; RAT;

ANIMALS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BRAIN; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; DRUG INTERACTIONS; DRUG SYNERGISM; INJECTIONS, INTRAPERITONEAL; MALE; METHYLATION; MICROSOMES, LIVER; PROMAZINE; RATS; RATS, WISTAR;

EID: 0030423916     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Arana G. W., Goff D. C., Friedman H., Ornsten M., Greenblatt D. J., Black B., Shader R. I.: Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Amer. J. Psychiat., 1989, 143, 650-651.
2. Baldessarini R. J., Teicher M. H., Cassidy J. W: Anticonvulsant cotreatment may increase toxic metabolites of antidepressants and other psychotropic drugs. J. Clin. Psychopharmacol., 1988, 8, 381-382.
3. Besser R., Kramer G., Theisohn M.: Antidepressiva and Carbamazepin: Aspekte der Kombinationstherapie und der pharmakologischen Interaction unter besonderer Berücksichtigung non Viloxazin. In: Carbamazepin in der Psychiatrie. Eds. Müller-Oerlinghausen B., Haas S., Stoll K. D., Thieme, Stuttgart, New York, 1989, 47-69.
4. Brøsen K., Kragh-Sørensen P.: Concomitant intake of nortriptyline and carbamazepine. Ther. Drug Monit., 1993, 15, 258-260.
5. Brøsen K., Zeugin T., Meyer U. A.: Role of P4502D6, the target of the sparteine-debrisoquine oxidation polymorphism, in the metabolism of imipramine. Clin. Pharmacol. Ther., 1991, 49, 609-617.
6. Brown C. S., Wells B. G., Cold J. A., Froemming J. H., Self T. H., Jabbour J. T.: Possible influence of carbamazepine on plasma imipramine concentrations in children with attention deficit hyperactivity disorder. J. Clin. Psychopharmacol., 1990, 5, 359-362.
7. Cashman J. R., Yang Z., Yang L., Wrighton S. A.: Stereo- and regioselective N-oxidation and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes. Drug Metab. Disposition, 1993, 21, 492-501.
8. Dahl M. L., Bertilsson L.: Genetically variable metabolism of antidepressants and neuroleptic drugs. Pharmacogenetics, 1993, 3, 61-70.
9. Dahl S. G.: Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin. Pharmacokinet., 1986, 11, 36-61.
10. Dahl-Pauustinen M. L., Liden A. Alm C., Nordin C., Bertilsson L.: Disposition of perphenazine is related to the polymorphic hydroxylation in human beings. Clin. Pharmacol. Ther., 1989, 46, 78-81.
11. Daniel W., Janczar L., Danek L., Legrum W., Netter K. J.: Pharmacokinetic interaction between carbamazepine and neuroleptics after combined prolonged administration to rats. Naunyn-Schmied, Arch. PharmacoL., 1992, 345, 598-605.
12. Daniel W., Netter K. J.: Metabolic interaction between imipramine and carbamazepine in vivo and in vitro in rats. Naunyn-Schmied. Arch. Pharmacol., 1988, 337, 105-110.
13. Daniel W., Syrek M., Janczar L., Boksa J.: The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats - A comparison with the pharmacokinetics of imipramine, Pol. J. Phannacol., 1995, 47, 127-136.
14. Ereshevsky L., Tran-Johnson T., Davis M. C., Leroy A.: Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepine and imipramine - new data and review. Clin. Cham., 1988, 5, 863-880.
15. Goldenberg H., Fishman V., Heaton A.: A detailed evaluation of promazine metabolism. J. Pharmacol. Exp. Ther., 1995, 150, 122-128.
16. Gonzalez F. J.: The molecular biology of cytochrome P-450. Pharmacol. Rev., 1989, 40, 243-285.
17. Gonzalez F. J.: Molecular genetics of the P-450 superfamily. Pharmacol. Ther., 1989, 45, 1-38.
18. Jann M. W., Ereshevsky L., Saklad S. R.: Effects of carbamazepine on plasma haloperidol levels. J. Clin. Pharmacol., 1985, 5, 106-109.
19. Kahn E. M., Schultz S. C., Perel J. M., Alexander J. E.: Change in haloperidol level due to carbamazepine - a complicating factor in combined treatment of schizophrenia. J. Clin. Psychopharmacol., 1990, 10, 54-57.
20. Kerr B. M., Thummel K. E., Wurden C. J., Klein S. M., Kroetz D. L., Gonzalez F. J., Levy R. H.: Human liver carbamazepine metabolism. Biochem. Pharmacol., 1994, 47, 1969-1979.
21. Kidron R., Avenbuch I., Klein E., Belmaker R. H.: Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol. Psychiat., 1985, 20, 219-222.
22. Laurenzana E. M., Sorrels S. L., Owens S. M.: Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human 2D6. Drug Metab. Disposition, 1995, 271-278.
23. Leinonen E., Lillsunde P., Laukkanen V., Ylitalo P.: Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J. Clin. Psychopharmacol., 1991, 11, 313-318.
24. Lemoine A., Gautier J. C., Azoulay D., Kiffel L., Belloc C., Guengerich F. P., Maurel P., Beaune P., Leroux J. P.: Major pathway of imipramine metabolism is characterized by cytochromes P-450 1A2 and P 450 3A4 in human liver. Mol. Pharmacol., 1993, 43, 827-832.
25. Lowry O. H., Rosenbrough N. J., Farr A. L., Randall R. J.: Protein measurement with the Folin fenol reagent. J. Biol. Chem., 1951, 193, 265-275.
26. Meyer J. W., Woggon B., Baumann P., Meyer U. A.: Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrysoquine type. Eur. J. Clin. Pharmacol., 1990, 39, 613-614.
27. Mikkelsen M., Andersen B. B., Dam M., Vesterager A., Kristensen H. B.: Paroxetine and antiepileptic drugs: no interaction. Psychopharmacology, 1991, 103, B13.
28. Nebert D. W., Nelson D. R., Coon M. J., Estabrook R. W., Feyereisen R., Fujii-Kuriyama Y., Gonzalez F. J., Guengerich F. P., Gunsalus I. C., Johnson E. F., Loper J. C., Sato R., Waterman M. R., Waxman D. J.: The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol., 1991, 10, 1-14.
29. Nishibe Y., Hirata M.: Induction of cytochrome P-450 3A(CYP 3A) by E 5110, a non-steroidal anti-inflammatory agent (NSAID), and typical CYP 3A inducers in primary cultures of dog hepatocytes. Biol. Pharm. Bull., 1995, 18, 1142-1144.
30. Omura T., Sato R.: The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem., 1964, 239, 2370-2378.
31. Omura T., Takesue S.: A new method for simultaneous purification of cytochrome b and NADPH-cytochrome reductase from rat liver microsomes. J. Biochem., Tokyo, 1970, 67, 249-257.
32. Otani K., Ishida M., Kaneko S., Michara K., Ohkubo T., Osanai T., Sugawara K.: Effects of carbamazepine coadministration on plasma concentration of trazodone and its active metabolite, m-chlorophenylpiperazine. Ther. Drug Monit, 1996, 18, 164-169.
33. Ovens M. L., Juenge E. C., Poklis A.: Convenient oxidation of phenothiazine salts to their sulfoxides with aqueous nitrous acid. J. Pharm. Sci., 1989, 78, 334-336.
34. Perucca E., Hedges A., Makki K. A., Ruprach M., Wilson J. F., Richens A.: A comparative study of the enzyme inducing properties of anticonvulsant drugs in epileptic patients. Brit J. Clin. Pharmacol., 1984, 18, 401-410.
35. Pisani F., Fazio A., Oteri G., Perucca E., Russo M., Trio R., Pisani B., Di Perri R.: Carbamazepine-viloxazine interaction in patients with epilepsy. J. Neurol. Neurosurg. Psychiat., 1986, 49, 1142-1145.
36. Pisani F., Narbonne M. C., Fazio A., Crisafulli P., Primerano G., D'Agostino A. A., Oteri G., Di Perri R.: Effect of viloxazine on serum carbamazepine levels in epileptic patients. Epilepsia, 1984, 25, 482-485.
37. Puz̀yński S.: Combined treatment of depression (in Polish). In: Combined treatment of psychiatric illnesses. Ed. Daniel W. A., Institute of Pharmacology, Polish Academy of Sciences and Jagiellonian Medical Research Center, Krakow, 1986, 3-15.
38. Rzewuska M.: Combined treatment of schizophrenia (in Polish). In: Combined treatment of psychiatric illnesses. Ed. Daniel W. A., Institute of Pharmacology, Polish Academy of Sciences and Jagiellonian Medical Research Center, Krakow, 1996, 17-33.
39. Spina E., Avenoso A., Campo G. M., Caputi A. P., Perucca E.: The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology, 1995, 117, 413-416.
40. van der Klein E., Schobben F., Vree T. B.: Clinical pharmacokinetics of antiepileptic drugs. Drug Intell. Clin. Pharm., 1980, 14, 674-685.